XML 46 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2016:
 
 
Fair Value Measurements at
 
December 31, 2016
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
10,300,813

 
$
10,300,813

 
$

 
$

Mutual funds
60,589,746

 

 
60,589,746

 

US corporate debt securities
25,039,666

 

 
25,039,666

 

Investments in affiliated entities
19,829,575

 
19,829,575

 

 

Total Assets
$
115,759,800

 
$
30,130,388

 
$
85,629,412

 
$

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,167,614

 
$

 
$

 
$
1,167,614

Total Liabilities
$
1,167,614

 
$

 
$

 
$
1,167,614


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2015:
 
 
Fair Value Measurements at
 
December 31, 2015
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
54,474,609

 
$
54,474,609

 
$

 
$

Mutual funds
78,385,992

 

 
78,385,992

 

US corporate debt securities
26,869,403

 

 
26,869,403

 

Municipal bonds
101,882

 

 
101,882

 

Investments in affiliated entities
19,987,192

 
19,987,192

 

 

Common stock warrants
5,970

 

 

 
5,970

Total Assets
$
179,825,048

 
$
74,461,801

 
$
105,357,277

 
$
5,970

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,301,138

 
$

 
$

 
$
1,301,138

Total Liabilities
$
1,301,138

 
$

 
$

 
$
1,301,138

Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair value of common stock warrants at December 31, 2016 and 2015 are presented below:
 
 
Year Ended December 31,
 
2016
 
2015
Risk-free interest rate
1.1%
 
1.36%
Expected volatility
61%
 
81%
Expected life in years
1.70
 
2.70
Dividend yield
 
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the years ended December 31, 2016 and 2015:

 
Year Ended December 31,
 
2016
 
2015
Balance at beginning of year
$
5,970

 
$
550,000

Decrease in fair value included in change in fair value of common stock warrants
(5,970
)
 
(544,030
)
Balance at end of year
$

 
$
5,970

Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the years ended December 31, 2016 and 2015:
 
 
Year Ended December 31,
 
2016
 
2015
Balance at beginning of year
$
1,301,138

 
$
2,022,729

Decrease in fair value included in change in fair value of common stock warrants
(133,524
)
 
(721,591
)
Balance at end of year
$
1,167,614

 
$
1,301,138

OncoSec  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at December 31, 2016 and 2015 are presented below:

 
Year Ended December 31,
 
2016
 
2015
Risk-free interest rate
0.51%
 
0.64%
Expected volatility
88%
 
90%
Expected life in years
0.25
 
0.75-1.25
Dividend yield